Stage IIIB Cutaneous Melanoma AJCC v7 Active Not Recruiting Phase 3 Trials for Ipilimumab (DB06186)

Back to Stage IIIB Cutaneous Melanoma AJCC v7

Indication	Status	Phase
DBCOND0091048 (Stage IIIB Cutaneous Melanoma AJCC v7)	Active Not Recruiting	3

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02224781	Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma	Treatment	Dabrafenib (DB08912) Ipilimumab (DB06186) Methane (DB15994) Nivolumab (DB09035) Trametinib (DB08911)
NCT02506153	High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery	Treatment	Benzalkonium (DB11105) Interferon alfa (DB05258) Interferon alfa-2b (DB00105) Ipilimumab (DB06186) Pembrolizumab (DB09037)
NCT01274338	Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery	Treatment	Benzalkonium (DB11105) Interferon alfa (DB05258) Interferon alfa-2b (DB00105) Ipilimumab (DB06186)